Rimonabant - Wikipedia
Rimonabant is an inverse agonist of the cannabinoid CB 1 receptor. Originally thought to be selective for the CB 1 receptor, rimonabant was subsequently also found to act as an antagonist of the μ-opioid receptor.
Rimonabant: Uses, Interactions, Mechanism of Action - DrugBank …
2008年2月14日 · Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world.
Rimonabant: From RIO to Ban - PMC - National Center for …
2011年7月6日 · Rimonabant, at a dose of 20 mg/day, in combination with diet and exercise, produced a clinically meaningful reduction in bodyweight and improved HbA1c and a number of cardiovascular and metabolic risk factors.
Anti-obesity therapy with peripheral CB1 blockers: from
2020年4月21日 · Pharmacotherapy of obesity using CB1 antagonists. When the first potent and selective CB1 inverse agonist (rimonabant) was developed in 1994 [19], the first idea was to explore its efficacy as a...
Neuropsychiatric adverse effects signal the end of the line for rimonabant
2010年10月25日 · Rimonabant was the first selective CB1 receptor antagonist to be approved and used in clinical practice. Blockade of the endocannabinoid system carried high hopes as a pharmacological...
Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a …
2018年5月1日 · Rimonabant is a potent and selective cannabinoid CB1 receptor antagonist widely used in animal and clinical studies. Besides its antagonistic properties, numerous studies have shown that, at micromolar concentrations rimonabant behaves …
Efficacy and safety of the weight-loss drug rimonabant: a meta …
2007年11月17日 · Four trials in the RIO programme assessed the efficacy and safety of the anti-obesity agent rimonabant compared with placebo, and our meta-analysis has shown that rimonabant therapy produced a greater weight loss than did placebo.
Rimonabant: more than an anti-obesity drug? - PMC - National …
2007年3月3日 · The selective cannabinoid CB 1 receptor antagonist, rimonabant, has undergone phase III clinical testing as anti-obesity drug. Obesity is considered a mild inflammatory condition and predisposes individuals to an …
Efficacy and safety of the weight-loss drug rimonabant: a meta ... - PubMed
2007年11月17日 · Our findings suggest that 20 mg per day rimonabant increases the risk of psychiatric adverse events--ie, depressed mood disorders and anxiety-despite depressed mood being an exclusion criterion in these trials.
Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, …
2008年10月9日 · Rimonabant is the first cannabinoid receptor type 1 (CB1) antagonist to reach advanced development for the treatment of obesity and the associated cardio-metabolic disorders in humans. 1,2 The role of the endocannabinoid system in different physiological and pathological mechanisms is now being more and more recognized. 3 The main endocannabinoi...
- 某些结果已被删除